Table 1. Main clinicopathologic features in relation to HER2 protein level assessed by HercepTest criteria in 790 endometrial carcinomas.
| HER2 HercepTest |
|||
|---|---|---|---|
| Low (0–2+) | High (3+) | P-valueb | |
| Variables (n)a | n (%) | n (%) | |
| Age (n=790) | <0.001c | ||
| Mean age | 64 | 70 | |
| FIGO-09 staged (n=790) | 0.04 | ||
| I–II | 561 (84) | 105 (16) | |
| III–IV | 95 (77) | 29 (23) | |
| Histologic type (n=790) | <0.001 | ||
| Endometrioid | 561 (88) | 80 (12) | |
| Serous papillary | 37 (51) | 35 (49) | |
| Clear cell | 21 (70) | 9 (30) | |
| Carcinosarcoma | 26 (77) | 8 (23) | |
| Undifferentiated | 11 (85) | 2 (15) | |
| Histologic gradee (n=623) | 0.003 | ||
| Grade ½ | 458 (89) | 55 (11) | |
| Grade 3 | 87 (79) | 23 (21) | |
| Recurrence (n=789) | 0.03 | ||
| No recurrence | 518 (85) | 92 (15) | |
| Metastatic at primary | 41 (75) | 14 (25) | |
| Later recurrence | 96 (77) | 28 (23) | |
| DNA ploidy (n=500) | <0.001 | ||
| Diploid | 335 (87) | 52 (13) | |
| Aneuploid | 82 (73) | 31 (27) | |
| Myometrial infiltration (n=788) | 0.66 | ||
| <50% | 403 (83) | 80 (17) | |
| >50% | 250 (82) | 54 (18) | |
| ER (n=649) | 0.99 | ||
| Positive | 410 (85) | 73 (15) | |
| Negative | 141 (85) | 25 (15) | |
| PR (n=647) | 0.006 | ||
| Positive | 434 (87) | 65 (13) | |
| Negative | 115 (78) | 33 (22) | |
Abbreviations: ER=oestrogen receptor; PR=progesterone receptor.
a
n=number of cases with available data for each variable.
b
Pearson’s chi-square test (asymp sig. two-sided).
c
Mann–Whitney U-test for independent samples.
d
FIGO: The Féderation Internationale de Gynécologie et d’Obstétrique.
e
Only endometrioid histology.